NDAORALTABLETPriority Review
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) by Gilead Sciences is rna replicase inhibitors [moa]. Approved for hepatitis c virus nucleotide analog ns5b polymerase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOSEVI is a fixed-dose combination oral tablet containing sofosbuvir, velpatasvir, and voxilaprevir that treats hepatitis C virus (HCV) infection. It works by inhibiting the HCV NS5B RNA polymerase and NS3/4A protease, blocking viral replication across multiple genotypes. This triple-agent combination is designed for treatment-experienced patients and those with cirrhosis.
$0.046BPart D
PeakStable
11.1 years to LOEProduct is at peak lifecycle stage with modest Part D spending; commercial team is likely maintenance-focused with opportunity for specialty care coordination and reimbursement expertise.
Mechanism of Action
RNA Replicase Inhibitors
Pharmacologic Class:
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Started May 2016
77 enrolled
Chronic Hepatitis C
Career Relevance
VOSEVI-linked roles span 399 open positions primarily in data science, R&D, commercial, and QA functions, reflecting mature product management and operational support needs. This indicates a stable career platform for professionals seeking specialty pharmacy expertise, managed care strategy, and hepatology market knowledge within a large pharmaceutical organization.
Director
Worked on VOSEVI at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.